Alyeska Master Fund, L.P.
listed in the table of 2025 Private Placement purchases by our directors, officers, and holders of more than 5% and affiliates
Purchased 875,000 shares of common stock and 2,748,188 pre-funded warrants in the 2025 Private Placement
With the Company
Open in proxy
Malcolm and Emily Charitable Remainder Unitrust 2010
trust of which Emily Fairbairn, a member of our Board, is trustee
Purchased 724,637 shares of common stock in the 2025 Private Placement
With the Company
Open in proxy
Peter Brandt
listed in the table of 2025 Private Placement purchases by our directors, officers, and holders of more than 5% and affiliates
Purchased 72,464 shares of common stock in the 2025 Private Placement
With the Company
Open in proxy
William Ho
Chief Executive Officer and a member of our Board
Purchased 36,232 shares of common stock in the 2025 Private Placement
With the Company
Open in proxy
Kate Rochlin
listed in the table of 2025 Private Placement purchases by our directors, officers, and holders of more than 5% and affiliates
Purchased 7,247 shares of common stock in the 2025 Private Placement
With the Company
Open in proxy
Patrick McCall
listed in the table of 2025 Private Placement purchases by our directors, officers, and holders of more than 5% and affiliates
Purchased 7,247 shares of common stock in the 2025 Private Placement
With the Company
Open in proxy
AIGH Investment Partners, LP
affiliate of AIGH Capital Management, LLC
Purchased 126,818 shares of common stock and Series C Warrants in the 2024 Private Placement
With the Company
Open in proxy
WVP Emerging Manager Onshore Fund, LLC – AIGH Series
affiliate of AIGH Capital Management, LLC
Purchased 32,963 shares of common stock and Series C Warrants in the 2024 Private Placement
With the Company
Open in proxy
WVP Emerging Manager Onshore Fund, LLC – Optimized Equity Series
affiliate of AIGH Capital Management, LLC
Purchased 8,994 shares of common stock and Series C Warrants in the 2024 Private Placement
With the Company
Open in proxy
The Hewlett Fund LP
listed in the table of 2024 Private Placement purchases by our directors, officers, and holders of more than 5% and affiliates
Purchased 33,755 shares of common stock and Series C Warrants in the 2024 Private Placement
With the Company
Open in proxy
Alyeska Master Fund, L.P.
listed in the table of 2024 Private Placement purchases by our directors, officers, and holders of more than 5% and affiliates
Purchased 168,776 shares of common stock and Series C Warrants in the 2024 Private Placement
With the Company
Open in proxy
Bios Clinical Opportunity Fund, LP
greater than 5% holder of our common stock; affiliate of Bios Equity Partners, LP
Purchased 23,634 pre-funded warrants and Series C Warrants in the 2024 Private Placement
With the Company
Open in proxy
Malcolm and Emily Charitable Remainder Unitrust 2010
trust of which Emily Fairbairn, a member of our Board, is trustee
Purchased 101,291 pre-funded warrants and Series C Warrants in the 2024 Private Placement
With the Company
Open in proxy
Peter Brandt
listed in the table of 2024 Private Placement purchases by our directors, officers, and holders of more than 5% and affiliates
Purchased 8,438 shares of common stock and Series C Warrants in the 2024 Private Placement
With the Company
Open in proxy
William Ho
Chief Executive Officer and a member of our Board
Purchased 4,219 shares of common stock and Series C Warrants in the 2024 Private Placement
With the Company
Open in proxy
Kate Rochlin
listed in the table of 2024 Private Placement purchases by our directors, officers, and holders of more than 5% and affiliates
Purchased 843 shares of common stock and Series C Warrants in the 2024 Private Placement
With the Company
Open in proxy
Patrick McCall
listed in the table of 2024 Private Placement purchases by our directors, officers, and holders of more than 5% and affiliates
Purchased 843 shares of common stock and Series C Warrants in the 2024 Private Placement
With the Company
Open in proxy
Alan S. Roemer
listed in the table of 2024 Private Placement purchases by our directors, officers, and holders of more than 5% and affiliates
Purchased 4,219 shares of common stock and Series C Warrants in the 2024 Private Placement
With the Company
Open in proxy
directors, officers and holders of more than 5% of our common stock and affiliates
holders of Series A Warrants that were amended
Amended Series A Warrants held by directors and officers (9,971 warrants) and by 5% holders and affiliates (155,751 warrants) to reduce exercise price from $37.50 to $13.50 and extend termination date to October 4, 2025
Bios Clinical Opportunity Fund, LP
greater than 5% holder of our common stock
Surrendered Series A and Series B Warrants for cancellation in exchange for pre-funded warrants and a cash payment of $5.349 per share in the April 2025 Warrant Exchanges
With the Company
Open in proxy
William Ho
Chief Executive Officer and a member of our Board
Surrendered Series A and Series B Warrants for cancellation in exchange for pre-funded warrants and a cash payment of $5.529 per share in the April 2025 Warrant Exchanges
With the Company
Open in proxy
